Antiphospholipid antibody effects on monocytes

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 198-204

  Wolberg, Alisa S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA2 GLYCOPROTEIN 1; DILAZEP; DORAMAPIMOD; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUINDOSTATIN; FMS RELATED TYROSINE KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; SIMVASTATIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VASCULOTROPIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLEEDING; CELL ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; CROHN DISEASE; DIABETES MELLITUS; DRUG INHIBITION; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; THROMBOCYTE; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; MACROPHAGE ACTIVATION; MONOCYTES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 34250770578     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0032-z     Document Type: Review

References (50)

1. Harris EN, Pierangeli SS, Gharavi AE: Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests. Lupus 1998, 7:S144-148.
2. Ma K, Simantov R, Zhang JC, et al.: High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541-15548.
3. 2-GPI-mediated cellular interactions.
4. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al.: Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375-4382.
5. Falcone DJ, Borth W, Khan KM, Hajjar KA: Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood 2001, 97:777-784.
6. Visvanathan S, McNeil HP: Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J Immunol 1999, 162:6919-6925.
7. del Prete G, de Carli M, Lammel RM, et al.: Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 1995, 86:250-257.
8. Raschi E, Testoni C, Bosisio D, et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101:3495-3500.
9. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
10. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll-like receptor 4 is involved in antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, In press. Provided in vivo evidence that links aPL-mediated thrombogenic effects with TLR-4.
11. Zhang J, Lieske KA, McCrae BA, McCrae KR: Activation of endothelial cells by b2-glycoprotein I (b2GPI) antibodies is mediated by annexin II cross linking and may involve TLR4 [abstract 278]. Blood 2004, 104:83a.
12. Balasubramanian K, Chandra J, Schroit AJ: Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 1997, 272:31113-31117.
13. Willems GM, Janssen MP, Pelsers MM, et al.: Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996, 35:13833- 13842.
14. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
15. Vaarala O, Manttari M, Manninen V, et al.: Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995, 91:23-27.
16. Hasunuma Y, Matsuura E, Makita Z, et al.: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573.
17. Kobayashi K, Matsuura E, Liu Q, et al.: A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
18. Lutters BC, Derksen RH, Tekelenburg WL, et al.: Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003, 278:33831-33838.
19. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
20. Bohgaki M, Atsumi T, Yamashita Y, et al.: The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004, 16:1633-1641.
21. Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al.: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54:301-311. Identified intracellular signaling pathways involved in aPL activation of monocytes.
22. Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004, 82:434-448.
23. Oeth P, Parry GC, Mackman N: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol 1997, 17:365-374.
24. de Prost D, Ollivier V, Ternisien C, Chollet-Martin S: Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemost 1990, 64:216-221.
25. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al.: Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841.
26. Amengual O, Atsumi T, Khamashta MA, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998, 79:276-281.
27. Dobado-Berrios PM, Lopez-Pedrera C, Velasco F, et al.: Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999, 82:1578-1582.
28. Schved JF, Gris JC, Ollivier V, et al.: Procoagulant activity of endotoxin or tumor necrosis factor activated monocytes is enhanced by IgG from patients with lupus anticoagulant. Am J Hematol 1992, 41:92-96.
29. Kornberg A, Blank M, Kaufman S, Shoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994, 153:1328-1332.
30. Reverter JC, Tassies D, Font J, et al.: Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthr Rheum 1998, 41:1420-1427.
31. Zhou H, Wolberg AS, Roubey RA: Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353-2358.
32. Roubey RA, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992, 90:1100-1104.
33. Cuadrado MJ, Buendia P, Velasco F, et al.: Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006, 4:2461-2469. Identified VEGF as a regulatory factor in aPL monocyte activation and expression of TF.
34. Vega-Ostertag M, Harris EN, Pierangeli SS: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50:2911-2919.
35. Vega-Ostertag M, Casper K, Swerlick R, et al.: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
36. Force T, Kuida K, Namchuk M, et al.: Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004, 109:1196-1205. Reviews inhibitors of protein kinase signaling pathways currently in clinical trials.
37. Branger J, van den Blink B, Weijer S, et al.: Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003, 101:4446-4448.
38. Faas MM, Moes H, Fijen JW, et al.: Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol 2002, 127:337-343.
39. Ferro D, Basili S, Alessandri C, et al.: Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000, 149:111-116.
40. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
41. Ferrara DE, Liu X, Espinola RG, et al.: Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003, 48:3272-3279.
42. Roubey RA: New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003, 48:3004-3008.
43. Hilgendorff A, Muth H, Parviz B, et al.: Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003, 41:397-401.
44. Ferro D, Saliola M, Meroni PL, et al.: Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J Thromb Haemost 2003, 1:523-531.
45. Deguchi H, Takeya H, Wada H, et al.: Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997, 90:2345-2356.
46. de Prost D: Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J Cardiovasc Pharmacol 1995, 25:S114-S118.
47. Ollivier V, Ternisien C, Vu T, et al.: Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett 1993, 322:231-234.
48. Soejima H, Ogawa H, Yasue H, et al.: Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999, 34:983-988.
49. Napoleone E, Di Santo A, Camera M, et al.: Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000, 86:139-143.
50. Golino P, Ragni M, Cirillo P, et al.: Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998, 82:39-46.